711 related articles for article (PubMed ID: 23836234)
21. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.
Belda O; Targett-Adams P
Virus Res; 2012 Dec; 170(1-2):1-14. PubMed ID: 23009750
[TBL] [Abstract][Full Text] [Related]
22. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
23. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies.
Ramirez S; Bukh J
Antiviral Res; 2018 Oct; 158():264-287. PubMed ID: 30059723
[TBL] [Abstract][Full Text] [Related]
24. Direct-acting antivirals: the endgame for hepatitis C?
D'Ambrosio R; Degasperi E; Colombo M; Aghemo A
Curr Opin Virol; 2017 Jun; 24():31-37. PubMed ID: 28419938
[TBL] [Abstract][Full Text] [Related]
25. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C virus: virology, diagnosis and management of antiviral therapy.
Chevaliez S; Pawlotsky JM
World J Gastroenterol; 2007 May; 13(17):2461-6. PubMed ID: 17552030
[TBL] [Abstract][Full Text] [Related]
27. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C virus entry.
Zeisel MB; Felmlee DJ; Baumert TF
Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C virus: prospects for future therapies.
Wilkinson T
Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
[TBL] [Abstract][Full Text] [Related]
30. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.
Ballesteros AL; Franco S; Fuster D; Planas R; Martínez MA; Acosta L; Sirera G; Salas A; Tor J; Rey-Joly C; Clotet B; Tural C
AIDS; 2004 Jan; 18(1):59-66. PubMed ID: 15090830
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
Cristina J; del Pilar Moreno M; Moratorio G
Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
[TBL] [Abstract][Full Text] [Related]
33. Treatment of hepatitis C: a systematic review.
Kohli A; Shaffer A; Sherman A; Kottilil S
JAMA; 2014 Aug; 312(6):631-40. PubMed ID: 25117132
[TBL] [Abstract][Full Text] [Related]
34. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV.
Lewis H; Cunningham M; Foster G
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):471-85. PubMed ID: 23199506
[TBL] [Abstract][Full Text] [Related]
35. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
[TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of HCV antiviral drug resistance.
Welsch C; Zeuzem S
Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
[TBL] [Abstract][Full Text] [Related]
37. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.
Feld JJ; Jacobson IM; Sulkowski MS; Poordad F; Tatsch F; Pawlotsky JM
Liver Int; 2017 Jan; 37(1):5-18. PubMed ID: 27473533
[TBL] [Abstract][Full Text] [Related]
38. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.
Ploss A; Dubuisson J
Gut; 2012 May; 61 Suppl 1():i25-35. PubMed ID: 22504917
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of hepatitis C: current status and perspectives].
Pol S; Corouge M
Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
[TBL] [Abstract][Full Text] [Related]
40. Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming.
Ellwanger JH; Kaminski VL; Valverde-Villegas JM; Simon D; Lunge VR; Chies JAB
Infect Genet Evol; 2018 Dec; 66():376-391. PubMed ID: 28811194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]